# Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

> **NCT05755087** · PHASE1 · RECRUITING · sponsor: **Lapo Alinari** · enrollment: 18 (estimated)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Tegavivint
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Marrow Aspiration

## Key facts

- **NCT ID:** NCT05755087
- **Lead sponsor:** Lapo Alinari
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2028-03-05
- **Final completion:** 2028-03-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755087, "Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05755087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*